The story so far
written Oct 2What is happening
The FDA Molecular and Clinical Genetics Devices Panel recommended approval of the Galleri multi-cancer early detection test on September 23, 2026 [1][3]. Full FDA approval is required for the test to qualify for potential insurance reimbursement [6]. The 10-member committee voted unanimously that the test is safe, 6-4 that it is clinically effective, and 7-2 that its benefits outweigh its risks for adults aged 50 and older [1][2].
Galleri uses a targeted methylation platform to identify cancer-specific signals in blood [3][4]. It is intended to supplement existing screening guidelines rather than replace them [3][4]. The test is currently sold by prescription for $949 [6].
What to watch
A final decision from the FDA on the Premarket Approval application is expected in the coming months [1][3]. The Center for Devices and Radiological Health issuing a final approval or denial would settle the regulatory status of the test.
A coverage determination published by the Centers for Medicare & Medicaid Services would establish federal reimbursement for the test. Grail filing a launch plan would signal the start of full commercial availability in the United States. Any public announcement of a legal challenge or withdrawal of the application would alter the approval path.
Read the full brief · how we got here
How we got here
Grail filed the Premarket Approval application on January 29, 2026 [4][10]. The September 23 meeting was the first time an FDA advisory committee reviewed such an application for a multi-cancer early detection test [1][4]. While the FDA typically follows the recommendations of its advisory panels, it is not legally required to do so [1][3].
References · 6
- [1]oncnursingnews.com — FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test
- [2]clpmag.com — FDA Panel Recommends Approval of GRAIL Galleri Multi-Cancer Test
- [3]allsci.com — FDA advisory panel backs GRAIL's Galleri multi-cancer early detection test
- [4]varese-group.com — GRAIL FDA Advisory Committee Votes in Favour of Approval for the ...
- [6]npr.org — FDA advisory panel recommends a multi-cancer blood test : NPR
- [10]grail.com — GRAIL Submits FDA Premarket Approval Application for the Galleri
What would close this
0 of 4 metTimeline
newest firstWhen we started following: FDA advisory panel votes to recommend approval of GRAIL Galleri multi-cancer early detection test for adults 50 and older
The FDA Molecular and Clinical Genetics Devices Panel voted on September 23, 2026, to recommend approval of GRAIL’s Galleri multi-cancer early detection (MCED) test [1][3]. In three separate votes, the 10-member committee unanimously supported the test's safety, voted 6-4 in favor of its clinical effectiveness, and voted 7-2 (with one abstention) that its benefits outweigh its risks for adults aged 50 and older [1][2].
This marks the first time an advisory committee has reviewed a Premarket Approval (PMA) application for an MCED test [1][4]. GRAIL originally filed the PMA on January 29, 2026 [4][10]. The Galleri test uses a targeted methylation platform to detect cancer-specific signals in blood and is intended to supplement, rather than replace, existing guideline-recommended screenings [3][4].
While the FDA is not required to follow the panel's recommendation, a final decision on the PMA is expected in the coming months [1][3]. The test is currently available by prescription for $949, and full FDA approval is a prerequisite for potential insurance reimbursement [6].